Home

Celebrating 40 years of

Innovation
Transforming Lives
Advancing IO
Breakthroughs

Register Now

April 23, 2025

Regular & YIA Abstract submissions open

May 5, 2025

Registration opens

June 26, 2025

Regular & YIA Abstract submissions close

1985 - 2025

Join us from Nov. 5 to Nov. 9, 2025 to celebrate 40 years of driving breakthroughs in cancer immunotherapy.

Thank you to our SITC 2025 Organizers

Miriam Merad, MD, PhD
Annual Program Committee Chair

Miriam Merad, MD, PhD, FAIO

Icahn School of Medicine at Mount Sinai

Ryan J. Sullivan, MD
Annual Program Committee Co-Chair

Ryan J. Sullivan, MD

Harvard Medical School,
Massachusetts General Hospital

Jennifer L. Guerriero, PhD
Annual Meeting Organizer

Jennifer L. Guerriero,
PhD

Brigham and
Women's Hospital

Lisa A. Kottschade, APRN, MSN, CNP, FAPO
Annual Meeting Organizer

Lisa A. Kottschade,
APRN, MSN, CNP, FAPO

Mayo Clinic

Aurélien Marabelle, MD, PhD
Annual Meeting Organizer

Aurélien Marabelle, MD, PhD

Gustave Roussy

Robert Samstein, MD, PhD
Annual Meeting Organizer

Robert Samstein,
MD, PhD

Icahn School of Medicine at Mount Sinai

Laurence Zitvogel, MD, PhD
Annual Meeting Organizer

Laurence Zitvogel, MD, PhD, FAIO

Gustave Roussy

Thank you to our SITC 2025
Keynote & Smalley Lecturer

Jennifer A. Wargo, MD, MMSC

Keynote Speaker

Jennifer A. Wargo, MD, MMSC
The University of Texas
MD Anderson Cancer Center

Targeting the Microbiome to Promote Health and End Cancer

Ira Mellman, PhD, FAIO

Richard V. Smalley Memorial Award & Lectureship 

Ira Mellman, PhD, FAACR, FAIO
Parker Institute for Cancer Immunotherapy, Medici Therapeutics

The Coming Renaissance of Cancer Immunotherapy

An Invitation to Exhibit at SITC's 40th Anniversary Annual Meeting

Advancing the Science and Application of Cancer Immunotherapy Worldwide

Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 40th Anniversary Annual Meeting, hosted by the leading member-driven organization focused on cancer immunotherapy, SITC. At SITC’s Annual Meeting, we will bring together international leaders from academia, regulatory and government agencies, as well as industry representatives for unmatched education, scientific exchange and networking with the scientists driving the field.

If you have a product or service that will advance research or accelerate laboratory results, do not miss this opportunity to exhibit at SITC’s 40th Anniversary Annual Meeting.

Reservations for returning 2024 exhibitors will open April 3, 2025. New exhibitors can begin applying on April 28. Contact development@sitcancer.org to receive the most up to date information. Dates subject to change.

Exhibit Hall

Who Exhibits at SITC?

Biotechnology companies, cancer organizations/foundations, consulting groups, data management companies, informatics/analysis firms, medical device manufacturers, medical equipment suppliers, medical publishers, pharmaceutical companies, research companies/agencies, scientific supply companies, universities/hospitals/research institutions.

Exhibit Hall Group

Hybrid Exhibits

Each face-to-face exhibit booth includes an optional virtual booth space to connect with registrants who cannot attend in person. Take advantage of this space to network with attendees, feature resources and publications, highlight posters and symposia, and link to your company website.

Exhibit Hall Group

Get in touch

Contact our Development Team to learn more about exhibiting and/or sponsorship opportunities at SITC 2025. Please email us at development@sitcancer.org and we will be in touch as soon as possible. We hope to see you in National Harbor! 

Why Attend SITC 2025?

SITC 2025 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2025 also includes updates on major national and international initiatives from academia, government and industry, as well as important society projects.

The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

Consider Joining Today

Members receive a substantial discount on SITC 2025 regular registration rates.

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy.

Our mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

We aim to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Learn More

SITC 40th Anniversary:
I-O Progress and Potential

JITC 40th Anniversary SeriesGet a head start on the celebration with a special series of commentaries in the Journal for ImmunoTherapy of Cancer (JITC) written by luminaries in the field of immuno-oncology.

Drs. Elizabeth Jaffee, Steven Rosenberg, Suzanne Topalian, Giorgio Trinchieri, Theresa Whiteside, and numerous other SITC Fellows of the Academy of Immuno-Oncology (FAIO) and Richard V. Smalley Memorial Award recipients put pen to paper to provide their insights into current achievements in various areas of the field while also sharing their personal, forward-looking vision of where the field is moving in the upcoming decades. Check out the JITC Special Series Collection throughout 2025 for new publications.